$PLPL PreMarket News!!! Plandai's Phytofare(TM) Catechin Complex to Fight Child Obesity
Press Release: Goldman Small Cap Research, Inc.
BALTIMORE, MD--(Marketwired - Aug 7, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a just published article that Plandai Biotechnology, Inc. (OTCQB: PLPL), which is slated engage in a weight loss study to test the efficacy of its flagship product, is well-positioned to assist in the fight against child obesity.
It is no secret that the U.S. is in a war with childhood obesity. After all, the statistics are alarming. According to the Centers for Disease Control and Prevention (CDC), childhood obesity has more than doubled in children and tripled in adolescents in the past 30 years. The CDC website also reports that recent statistics note that more than one third of children and adolescents were overweight or obese.
With a 90 subject, three month weight loss study slated to commence later this year, Plandai Biotechnology, Inc. is well-positioned to assist in reducing this disturbing trend. Previous green tea extract weight loss studies, exclusively using children as subjects have not had a great deal of success due to limited bioavailability (nutrient absorption rate into the bloodstream.) However, in its pending trials, the Company's Phytofare™ Catechin Complex should be able to demonstrate significant health benefits, including weight loss, owing to its industry-leading absorption levels. Success in this trial would likely turn the product into the go-to prevention ingredient and offering in weight loss for adults and children.
Many parents would gladly migrate their children's consumption habits away from sugary soft drinks to healthier alternatives that can aid in weight loss and general wellness. Of course, the benefits to the immune system and overall wellness derived from green tea extracts are well documented. These characteristics have sharply driven the consumption of green tea and the catechins associated with its disease prevention and health benefit properties. Still, the Holy Grail for parents would be a delivery system that offers are seeking greater bioavailability along with caffeine-free alternatives, which the Company would likely be able to accommodate, pending the outcome of the future trials.
As a potential provider of the offering of choice in obesity prevention for adults and children, Plandai's offerings appear poised to be rewarded with an extremely high profile resulting in significant sales in the U.S. and abroad.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
